[Form 4] LAVA Therapeutics NV Insider Trading Activity

Rhea-AI Filing Summary

LAVA Therapeutics N.V. director reported a disposition of common shares and related options tied to a Purchase Agreement with XOMA Royalty Corporation. The director disposed of 10,000 common shares on 11/13/2025 and no common shares remained beneficially owned afterward. A stock option covering 33,390 common shares with a per share exercise price of $0.93 was cancelled on the same date. In exchange, the reporting person received $1.04 in cash per share plus one non-transferable contingent value right (CVR) per share

11/17/2025 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON KAREN J

(Last) (First) (Middle)

C/O LAVA THERAPEUTICS N.V.

YALELAAN 62

(Street)

UTRECHT P7 3584 CM

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LAVA Therapeutics NV [ LVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/13/2025		D		10,000	D	(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Options (Right to Buy)	$0.93	11/13/2025		D			33,390	(2)	02/12/2035	Common Shares	33,390	$0	0	D

Explanation of Responses:

1. Disposed of pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the " Purchase Agreement") in exchange for (i) $1.04 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share.

2. This option was cancelled pursuant to that certain Purchase Agreement in exchange for cash and CVRs (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.

	/s/ Amy Garabedian, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LAVA Therapeutics (LVTX) report in this Form 4?

A director of LAVA Therapeutics N.V. (LVTX) reported disposing of 10,000 common shares and cancelling an option over 33,390 common shares on 11/13/2025, in connection with a Purchase Agreement with XOMA Royalty Corporation.

How many LAVA Therapeutics (LVTX) shares did the director sell and at what consideration?

The director disposed of 10,000 common shares. Each share was exchanged for $1.04 in cash per share plus one non-transferable contingent value right (CVR) per share, as set out in the Purchase Agreement.

What happened to the LAVA Therapeutics (LVTX) stock options reported in this Form 4?

A stock option to acquire 33,390 common shares at an exercise price of $0.93 per share was cancelled on 11/13/2025. The holder received cash and CVRs based on the excess of $1.04 over the exercise price multiplied by the shares underlying the option, plus one CVR per underlying share.

What is the contingent value right (CVR) mentioned for LAVA Therapeutics (LVTX)?

The transaction terms include one non-transferable contingent value right (CVR) per share and per in-the-money option share. The CVRs are described as non-transferable; additional CVR terms are not detailed in this excerpt.

What is the relationship of the reporting person to LAVA Therapeutics (LVTX)?

The reporting person is identified as a Director of LAVA Therapeutics N.V. and filed the Form 4 as an individual reporting person.

Which agreement governs the consideration for the LVTX share and option transactions?

The consideration for both the common shares and the cancelled options is governed by a Purchase Agreement dated August 3, 2025 between LAVA Therapeutics N.V. and XOMA Royalty Corporation, as referenced in the explanatory notes.